Literature DB >> 9457296

Urodynamic effects of oral oxybutynin chloride in children with myelomeningocele and detrusor hyperreflexia.

C Goessl1, H H Knispel, U Fiedler, B Härle, K Steffen-Wilke, K Miller.   

Abstract

OBJECTIVES: To investigate the effects of oral oxybutynin chloride (OC) on standard urodynamic measures in children with myelomeningocele (MMC) and detrusor hyperreflexia.
METHODS: Forty-one MMC children with detrusor hyperreflexia (19 boys and 22 girls, aged 2 months to 15 years; mean 4.9 years) were evaluated urodynamically before and within 3 months after initiation of oral OC therapy (0.2 to 0.3 mg/kg/day). Therapy with oral OC was always combined with clean intermittent catheterization (CIC).
RESULTS: Oral OC treatment caused an increase in bladder capacity from 141 +/- 96 to 197 +/- 99 mL (+ 40%; P < 0.01), a decrease in detrusor pressure at maximal capacity from 45 +/- 32 to 28 +/- 23 cm H2O (-38%; P < 0.01), and an increase in detrusor compliance from 6.5 +/- 5.6 to 16.8 +/- 13.7 mL/cm H2O (+ 158%; P < 0.01). Improvement in urodynamic measures and continence were correlated. After a follow-up of at least 2 years, effective protection of renal function was achieved in 38 of the 41 children (93%) with conservative therapy alone. Adverse effects resulted in discontinuation of oral OC treatment in only 2 cases.
CONCLUSIONS: Treatment with oral OC and CIC is effective and safe in children with MMC and detrusor hyperreflexia and should be initiated early when indicated by urodynamic findings.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9457296     DOI: 10.1016/s0090-4295(97)00489-5

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  5 in total

1.  Systematic review of therapy for neurogenic detrusor overactivity.

Authors:  Clare J Fowler
Journal:  Can Urol Assoc J       Date:  2011-10       Impact factor: 1.862

Review 2.  [Neurogenic bladder function disorders in patients with meningomyelocele: S2k guidelines on diagnostics and therapy].

Authors:  R Stein; C Assion; R Beetz; M Bürst; R Cremer; A Ermert; M Goepel; E Kuwertz-Bröking; B Ludwikowski; T Michael; J Pannek; H Peters; D Rohrmann; I Rübben; A Schröder; R Trollmann; J W Thüroff; W Wagner
Journal:  Urologe A       Date:  2015-02       Impact factor: 0.639

3.  Efficacy, tolerability, and safety of oxybutynin chloride in pediatric neurogenic bladder with spinal dysraphism: a retrospective, multicenter, observational study.

Authors:  Jung Hoon Lee; Kyoung Rok Kim; Yong Seung Lee; Sang Won Han; Kun Suk Kim; Sang Hoon Song; Minki Baek; Kwanjin Park
Journal:  Korean J Urol       Date:  2014-11-28

Review 4.  [Urological problems in patients with meningomyelocele. Diagnostic studies and management].

Authors:  R Stein; A Schröder; R Beetz; A Ermert; D Filipas; M Fisch; M Goepel; I Körner; B Schönberger; C Sparwasser; M Stöhrer; J W Thüroff
Journal:  Urologe A       Date:  2007-12       Impact factor: 0.639

Review 5.  Medical management of neurogenic bladder with oral therapy.

Authors:  Anne P Cameron
Journal:  Transl Androl Urol       Date:  2016-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.